Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.92 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.70 |
| ▸ | FLT4 | P35916 | 2/20 | 0.70 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.70 |
| ▸ | STK17B | O94768 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11683 | 1.00 | EGFR (0.92) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL11156 | 0.96 | EGFR (1.00) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL17520362 | 0.96 | EGFR (1.00) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL12856430 | 0.93 | EGFR (0.80) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL19220767 | 0.91 | EGFR (0.76) | EGFRKDRFGFR1FLT1ERBB2 | |
| Hydrochloric Acid SCHEMBL2163107 | 0.88 | EGFR (0.72) | EGFRKDRFGFR1FLT1ERBB2 | |
| Hydrochloric Acid SCHEMBL7455695 | 0.87 | FLT1 (0.91) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL19220785 | 0.86 | EGFR (0.82) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL14092460 | 0.86 | EGFR (0.92) | EGFRKDRERBB2FLT4EPHB4 | |
| SCHEMBL30207668 | 0.86 | EGFR (0.85) | EGFRKDRERBB2FLT4EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| EP-3181554-A1 | QUINAZOLINE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.